Precision Medicine: Tailoring Therapies to the Individual Patient
Genomic sequencing and biomarker-driven treatments are ushering in a new era where therapies are designed around a patient's unique biology.
Precision medicine is replacing the one-size-fits-all treatment model that has defined most of pharmaceutical history with therapies selected — or in some cases custom designed — based on an individual patient's specific genetic and molecular profile.
Genomic Sequencing Becomes Routine
The cost of whole genome sequencing has fallen dramatically over the past two decades, moving genomic testing from an expensive research-only tool into something increasingly incorporated into routine clinical decision-making, particularly in oncology where tumor genomic profiling now regularly guides treatment selection.
Biomarker-Driven Treatment Selection
Rather than prescribing a therapy and observing whether it works, precision medicine increasingly uses biomarker testing upfront to predict which patients are most likely to respond to a given treatment — sparing non-responders the side effects and delay of an ineffective therapy while directing the most appropriate treatment to those most likely to benefit.
The Economics of Personalization
Precision therapies, particularly cell and gene therapies designed for a single patient or narrow patient subgroup, carry fundamentally different economics than traditional blockbuster drugs — extremely high per-patient cost but a much smaller total addressable patient population, forcing payers and manufacturers to develop entirely new reimbursement and pricing models.
